Company news
Quantum Biopharma Ltd. Subordinate Voting Shares Class B (CSE:QNTM) news
Quantum Biopharma Ltd. Subordinate Voting Shares Class B news releases on 6ix. Latest, Jun 28, 2024: FSD Pharma, Inc. Wins Final Judgment to Confirm…
View Quantum Biopharma Ltd. Subordinate Voting Shares Class B →
Press releases — page 4
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
June 28, 2024
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
June 27, 2024
FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
June 13, 2024
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
June 4, 2024
FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
May 31, 2024
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
May 28, 2024
FSD Pharma Provides Corporate Update
May 24, 2024
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
May 16, 2024
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
May 7, 2024
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
April 30, 2024
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM)
April 25, 2024
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
April 22, 2024
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
April 17, 2024
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
April 7, 2024
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
April 6, 2024
FSD Pharma Announces Filing of Year-End 2023 Results
April 1, 2024
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
March 27, 2024
FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
March 11, 2024
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
March 5, 2024
FSD Pharma Announces Debt Settlement
February 28, 2024
FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)
February 26, 2024
FSD Pharma Announces US ATM Offering
February 16, 2024
Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million
February 6, 2024
FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates
January 29, 2024
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot
January 16, 2024
FSD Pharma Inc. Announces Closing of Private Placement
December 5, 2023
FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement
November 30, 2023
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness
November 28, 2023
FSD Pharma Inc. Obtains Final Order for Plan of Arrangement
November 27, 2023
Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.
November 24, 2023
FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.
November 21, 2023
FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement
November 17, 2023
FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023
November 15, 2023
FSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One Basis
November 7, 2023
FSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus
November 6, 2023
FSD Pharma Files Management Information Circular for Proposed Arrangement with Celly Nu
October 23, 2023
FSD Pharma and Celly Nu Enter Into Arrangement Agreement
October 5, 2023
FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice
October 4, 2023
FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated
September 18, 2023
FSD Pharma Announces Analyst Coverage Initiated by Singular Research
September 13, 2023
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
August 15, 2023
FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink
August 2, 2023
Sidoti's Micro-Cap Virtual May Conference
May 9, 2023
InvestmentPitch Media Video Discusses FSD Pharma's Unveiling of Video Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Mouse Models - Video Available on Investmentpitch.com
December 3, 2021
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
October 18, 2021
FSD Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th
October 13, 2021
InvestmentPitch Media Video Discusses FSD Pharma's Closing of its acquisition of Canadian Specialty Psychedelic Pharmaceutical Company Lucid Psycheceuticals - Video Available on Investmentpitch.com
September 22, 2021
InvestmentPitch Media Video Discusses FSD Pharma's Definitive Agreement to Acquire 100% of Lucid Psycheceuticals Inc. - Video Available on Investmentpitch.com
August 26, 2021
InvestmentPitch Media Video Discusses FSD Pharma's Termination of its CEO, Dr. Raza Bokhari, for Cause - Video Available on Investmentpitch.com
July 28, 2021
FSD Management and Board Suffers Multiple Court Losses as Shareholder Meeting Approaches
May 12, 2021